Horie I, et al. – Researchers evaluated the glycemic control of combination therapy with basal insulin and liraglutide, and examined the factors predictive of efficacy in patients with type 2 diabetes mellitus when switched from longstanding basal-bolus insulin therapy. Data from 41 patients who switched from basal-bolus insulin therapy for >3 years to basal insulin/liraglutide combination therapy were analyzed. Glycemic control was assessed at 6 months after switching therapy and used to determine whether patients were good-responders (hemoglobin A1c <7.0% or 1.0% decrease) or poor-responders. A total of 68.3% of patients were identified as good-responders. Findings indicated that, after switching therapies, enhancement of glucose-dependent insulin-response under liraglutide administration may be a potential predictor of long-term glycemic control.